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A B S T R A C T
Objective(s): The ultrasonic advanced energy study device (AH device) is the ﬁrst surgical device
indicated to seal vessels up to and including 7 mm using ultrasonic technology alone. This study assesses
clinical experience during total laparoscopic hysterectomy (TLH) using advanced hemostasis mode
(AHM).
Study design: This was a prospective, non-randomized, single arm, multicenter, observational study
which did not modify or inﬂuence current surgeon technique for elective TLH for benign disease.
Each surgeon assessed hemostasis, deﬁned as the hemostatic transection of the uterine vasculature
(left/right) with at least one use of the AH device in AHM without the use of additional hemostatic
measures other than the AH device. Patients were followed for 4–6 weeks after surgery.
Vessel sealing performance was quantitatively assessed for transection and sealing of the uterine
artery (UA), the uterine pedicle (UP; deﬁned as cases where the UA could not be ‘isolated’) and the
ovarian pedicle (OP) (when indicated). Adverse events (AEs) related to the AH device or procedures were
collected.
Results: Forty patients underwent the procedure. Mean age was 49 years and mean body mass index was
28 kg/m2. Mean surgical duration was 88 min. None required conversion to open procedure. Using only
the AH device, hemostasis was achieved and maintained in 119 (94.4%) transections (both left and right
sides of the UA/UP and OP). Additional hemostasis was achieved in 5 patients using conventional bipolar
(4) or monopolar (1) energy. No patient required a blood transfusion postoperatively. Only one adverse
event of pain was considered to be related to the use of the ultrasonic AH device during this study.
Conclusion: These results support that the AH device with its AHM has clinical utility in sealing named
vessels in TLH. The new algorithm to deliver energy in the AHM has the potential to reduce the need for
additional hemostatic devices or products as well as the potential to reduce the need for multiple
instrument changes during surgery.
 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Hysterectomy is the second most frequently performed major
surgical procedure after cesarean delivery among reproductive-age
women with over 500,000 performed annually in the US [1].* Corresponding author. Tel.: +1 5133378366; fax: +1 5133378115.
E-mail address: amaxson@its.jnj.com (A.J. Maxson).
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0301-2115/ 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access 
nd/4.0/).Approximately one in ten (10.4%) women 40–44 years of age in
2011–2013 report having had a hysterectomy [2]. Minimally invasive
surgical techniques lead to decreased post-operative pain, decreased
morbidity, and faster recovery times when compared to open
abdominal procedures [3]. According to committee opinions from
The American Congress of Obstetricians and Gynecologists (ACOG)
and the American Association of Gynecologic Laparoscopists (AAGL),
the preferred route for hysterectomy is a minimally invasive
approach via the vaginal route or laparoscopically if not feasiblearticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
Fig. 1. Caption: Harmonic Ace +7 device transecting dissected left uterine artery.
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laparoscopic suture ligation, laparoscopic energy sources have been
introduced for dissection and hemostasis [5,6]. These energy sources
include monopolar, bipolar, ultrasonic and advanced bipolar
technology. Ultrasonic energy was introduced to surgery in
1991. The energy is purely mechanical; avoiding electric current
traveling within the patient [7]. Coagulation is achieved via
denaturation of proteins as hydrogen bonds break due to vibrational
energy transferred to the tissue. The ﬁrst laparoscopic hysterectomy
using ultrasonic energy was performed and published by Robbins
and Ferland in 1995 [8]. This mode of action provides the lowest
thermal spread, least amount of smoke production and tissue
damage and the best subjective visibility score when compared to
various advanced bipolar instruments [9,10]. Due to the limited
number of studies in the literature, there is insufﬁcient evidence to
recommend one energy source over another [12].
Historically only advanced bipolar vessel sealing technologies
were indicated to seal vessels up to 7 mm diameter. In 2013,
Ethicon Endo-Surgery, Inc. developed the Advanced Hemostasis
(AH) device which utilizes the Harmonic ACE Shears combined
with an Adaptive Tissue Technology (ATT) algorithm to monitor
the instrument and respond intelligently to tissue conditions. ATT
provides more precise energy delivery leading to less thermal
damage, fewer adhesions, faster transection, less visual obstruc-
tion and higher burst pressures as demonstrated in preclinical
trials [7]. The AH device has further optimized this algorithm; the
AHM is designed for larger vessels up to 7 mm in size. In this mode
cutting speed is further reduced and hemostasis is maximized.
The objective of this study is to assess the initial clinical
experience with the AH device by quantitatively and qualitatively
evaluating vessel sealing of the uterine and ovarian vasculature
during TLH.
Materials and methods
Study design
Sponsored by the manufacturer of the AH device (Ethicon Endo-
Surgery, Inc. Cincinnati, OH), this was a prospective, non-random-
ized, single arm, multicenter, observational study conducted at
4 centers, with 5 surgeons (Radboud University Nijmegen Medical
Centre, Netherlands; The Royal Surrey County Hospital, Guildford,
UK; The Advanced Gynecological Surgery Institute, USA; Florida
Hospital Celebration Health, USA). The study was reviewed by each
Institutional Review Board or Ethics Committee prior to initiation
and was performed in compliance with the Health Insurance
Portability and Accountability Act and Good Clinical Practices.
(Clinicaltrials.gov identiﬁer: NCT02278640).
The study utilized a new ultrasonic advanced energy device,
Harmonic ACE1 +7 Shears, to transect and seal the uterine and
ovarian vasculature (Fig. 1).
The AH device was used throughout the procedures and AHM
was used speciﬁcally to seal and transect the uterine artery/uterine
pedicle (UA/UP) and ovarian pedicle (OP); hemostasis was assessed
by each surgeon. The use of any energy device or hemostatic
product to either establish initial hemostasis or maintain ﬁnal
hemostasis across each vessel and the number of touchup
applications of the AH device that were required to achieve or
maintain ﬁnal hemostasis were recorded. Each patient had 4–6
weeks follow-up care. AEs were collected and assessed for
relationship of the event to the procedure or AH device.
Patient selection
Patients from the United States and the European Union who
were eligible to participate in the study included those indicatedfor elective TLH for benign conditions, older than 40, with no future
desire for fertility.
Preoperative exclusions included uncontrolled bleeding dis-
orders, unwillingness or unlikely to comply with the protocol
requirements, suspected malignancy, and positive pregnancy test.
Patients were also excluded when intra-operative ﬁndings
precluded the conduct of the study procedure.
Study procedure and post-operative follow up
TLH is deﬁned as having the uterus and cervix removed and
may be entirely performed laparoscopically. However, some
surgeons prefer to suture the vaginal cuff using a vaginal approach.
TLHs were included in the study, with no inﬂuence on
participating surgeons’ techniques. Investigators performed TLHs
using the AH device in compliance with their own standard
surgical approach and product labeling. The study allowed only the
Principal Investigator to apply the AH device.
Each patient was followed per the surgeon’s standard of care.
Study data was recorded onto medical charts and source work-
sheets and subsequently entered into an electronic Case Report
Form. A laparoscopic video recording was made of the procedure
and documented the sealing of each vessel.
Vessel transection assessments for the UA/UP and/or OP
documented during the study procedure included: vessel name,
location, application time, transection time, tissue sticking [via a 4-
point Likert scale], additional harmonic touch-ups and use of any
other device or product to achieve hemostasis.
Surgeon’s workload to dissect and transect using the AH device
throughout the TLH was subjectively evaluated utilizing the NASA
Task Load Index (NASA-TLX), a validated ﬁxed-format, self-
administered, multidimensional tool to assess the following
subscales: mental, physical, and temporal demands, self-perfor-
mance, effort, and frustration.
Subscales were rated for transection and dissection with the AH
device during the hysterectomy procedure, with a 100-point range
utilizing 5-point steps. These ratings were combined to provide the
task load index.
Approximately 4–6 weeks following surgery, adverse events,
concomitant medications, and reoperation data were reviewed and
changes recorded. An inspection of the vaginal cuff was completed
and patients were exited from the study following this visit.
The primary endpoint for analysis was incidence of hemostasis
at the named vessel/pedicle (UA or UP). Secondary endpoints
included incidence of hemostasis at the OP on the left/right side,
incidence of requirement for additional measures to obtain
hemostasis and incidence of complications associated with vaginal
cuff healing.
Table 2
Endpoints and surgery details.
Hemostasis results
Left Right
Uterine artery or pedicle n = 40 n = 40
Vessel skeletonized 26 (65.0%) 25 (62.5%)
Hemostasis achieved 39 (97.5%) 37 (92.5%)
Single application of AH device 26 (65.0%) 24 (60.0%)
Hemostasis maintained 37 (92.5%) 31 (79.5%)
1. Additional touch up required 6 (15.0%) 8 (20.0%)
2. Additional touch ups required 6 (15.0%) 6 (15.0%)
3. Additional touch ups required 2 (5.0%) 2 (5.0%)
Additional hemostatic products
required
0 (0.0%) 0 (0.0%)
Additional energy devices required 3 (7.5%) 4 (10.0%)
No tissue sticking 39 (97.5%) 40 (100.0%)
Ovarian pedicle n = 23 n = 23
Hemostasis achieved 23 (100.0%) 23 (100.0%)
Single application of AH device 16 (69.6%) 18 (78.3%)
Hemostasis maintained 21 (91.3%) 22 (95.7%)
1. Additional touch up required 1 (4.3%) 4 (17.4%)
2. Additional touch ups required 4 (17.4%) 0 (0.0%)
3. Additional touch ups required 1 (4.3%) 1 (4.3%)
4. Additional touch ups required 0 (0.0%) 0 (0.0%)
T.E. Nieboer et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 201 (2016) 135–139 137Statistical analysis
Descriptive statistics including conﬁdence intervals were
provided for all study endpoints. Summary statistics included
counts and percentages for categorical variables and the number of
patients, number of named vessels/pedicles, mean, standard
deviation (SD), median, minimum, and maximum for continuous
variables. All enrolled patients were included for the analysis
of primary, secondary and safety endpoints. No imputation of
missing data was performed. All statistical analyses were
performed using SAS, version 9.3.
Results
A total of 41 patients were consented and 40 were enrolled and
operated on between November 2014 and May 2015. One patient
was excluded due to intraoperative ﬁndings. Table 1 summarizes
the preoperative characteristics of all enrolled patients. Mean age
was 48.5 years (range 36–67), 39 (97.5%) patients were white, and
mean body mass index was 28.2 kg/m2 (range 17.7–47.4 kg/m2).
Pregnancy history was available for 37 women, with 30 reporting
at least one pregnancy and 29 reporting at least one delivery. Six
patients reported a history of one or more caesarean sections.
In 7 (17.5%) patients a TLH was performed conserving the
ovaries and salpinges. In 8 (20.0%), the salpinges were removed,
but ovaries were conserved. In 25 (62.5%) women, one or both
ovaries and salpinges were removed.
Complexity of the cases was graded by each surgeon on a
subjective basis but was mainly inﬂuenced by uterine size,
adhesions, and severity of endometriosis; medium or high
complexity ratings were assigned in 36 (90.0%) of the cases.
Mean duration of the procedure was 88.4 min (range 33–209).
The average uterine size was 200 grams (range 46–564). A
laparoscopic colpotomy approach was utilized in 20 (50.0%)
patients and a vaginal approach was utilized in 20 (50.0%) patients.
In two patients the specimens required morcellation with the Lina
Morcellator to extract due to uterine size (484 and 348 g). No
patients were converted to open procedures or required blood
transfusions.
Using only the AH device, hemostasis was achieved and
maintained in 119 (94.4%) transections (both left and right sidesTable 1
Baseline characteristics of patients entering the study.
n = 40 SD
Age, yrs 48.5 (36.0, 67.0) 6.9
Race
White 39 (97.5%)
Black or African American 1 (2.5%)
BMI 28.2 (17.7, 47.4) 5.6
Parous women (having 1 or more deliveries) 29 (72.5%)
Patients previous cesarean sections: 6 (15.0%)
Indication for hysterectomy
Abnormal bleeding 13 (32.5%)
Endometriosis 6 (15.0%)
Dysmenorrhea 6 (15.0%)
Fibroids 5 (12.5%)
Atypical or hyperplastic endometrium 4 (10.0%)
Prolapse 2 (5.0%)
Adenomyosis/ovarian cyst 2 (5.0%)
PAP smear abnormalities 1 (2.5%)
Pyometrium 1 (2.5%)
Histological diagnosis
Fibroids 21 (52.5%)
Adenomyosis 14 (35.0%)
Endometriosis 13 (32.5%)
Endometrial abnormality 9 (22.5%)
Data are presented as mean (range) or number (%). Abbreviations: BMI, body mass
index; SD, standard deviation.of the UA/UP and OP). The entire surgical procedure could be
completed using only AH device for vascular division/control in 35
(87.5%) patients. In 5 patients, an additional energy device was
needed to maintain hemostasis; bipolar was used for 4 patients
and monopolar for the 5th patient. Details regarding the need for
additional touch-ups to achieve ﬁnal hemostasis are shown in
Table 2.
Mean NASA-TLX was 19.2 (range 0–100), indicating that
surgeons did not perceive the AH device to lead to an increased
workload. Surgeons felt the study device was the same in 30.0% of
cases and better in 62.5% of cases for transecting the UA/UP
compared to past experience using other advanced energy devices
or dissection modalities. Similarly, sealing of the UA/UP was
deemed the same or better in 92.5% of cases compared to past
experience using advanced energy devices or other hemostatic
modalities.5. Additional touch ups required 1 (4.3%) 0 (0.0%)
Additional hemostatic products required 0 (0.0%) 0 (0.0%)
Additional energy devices required 0 (0.0%) 0 (0.0%)
No tissue sticking 23 (100.0%) 23 (100.0%)
Surgery details n = 40
Length of stay, days 1.4 (0.0, 5.0)
Surgery Time, min 88.4 (33.0, 209.0)
SD 45.1
No. of blood transfusions 0 (0.00%)
No. of cases converted to open 0 (0.00%)
Uterine weight, g 200.1 (46.0, 564.0)
Colpotomy approach
Laparoscopic 20 (50.0%)
Vaginal 20 (50.0%)
Colpotomy method
Monopolar energy 3 (7.5%)
Ultrasonic energy 17 (42.5%)
Cold knife 20 (50.0%)
Patients requiring no additional
hemostatic products or
additional energy devices to
achieve hemostasis
35 (87.5%)
40 patients had applications on the
Left and the Right UA/UP for a
total of 80 applications on the
UA/UP
25 patients had applications to
the Left and/or Right OP
Data are presented as mean (range) or number (%). Abbreviations: UA/UP, uterine
artery/uterine pedicle; OP, ovarian pedicle; SD, standard deviation.
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patients using only the AH device. A single activation of the AH
device on both uterine arteries achieved hemostasis in 17 (42.5%)
patients. In 4 (10.0%) patients, one additional activation (totaling
3 activations over both uterine arteries) was necessary to achieve
hemostasis. Four activations of the AH device were required in 13
(32.5%) patients, and 6 (15.0%) patients required 5 or 6 activations
over the two uterine vessels. The majority (8 of 9) of cases where
hemostasis was not maintained occurred on the right side. Slight
tissue sticking was reported in one patient on the left UP.
Oophorectomy data is presented in Table 2. Oophorectomies
were performed in 25 patients (46 individual oophorectomies)
with hemostasis achieved in 100.0% of patients. Hemostasis was
initially achieved on the OP in 25 of 25 (100.0%) patients using only
the AH device. A total of 16 of 25 (64.0%) patients required a single
application of the AH device to obtain initial hemostasis.
Hemostasis of the OP was maintained in 22 of 25 (80.0%) patients
and additional applications of the AH device were required to
maintain hemostasis in the remaining 3 (12.0%) patients. Tissue
sticking was not reported on any of the OP transections. The AH
device was the only energy or hemostatic product required to
transect the ovarian pedicles in 25 of 25 (100.0%) patients.
The surgeons began the UA/UP cuts on the right side in 21
(52.5%) patients. There was no apparent association between the
side of ﬁrst transection and the lack of hemostasis on initial
application of the AH device or the failure to maintain hemostasis.
One patient reported pain that was considered possibly related
to the study device. No other AEs were considered to be related to
the AH device. Three serious adverse events were reported – an
infected haematoma, urinary retention, and vaginal haemorrhage.
All patients completed the study and events were resolved with no
further complications.
No patients required post-operative transfusions or reopera-
tions. All colpotomies healed with no complications during the
6 weeks follow-up.
Discussion
The study demonstrated that using the AH device alone,
hemostasis could be achieved and maintained in 119 (94.4%)
transections (both left and right sides of the UA/UP and OP).
Hemostasis was achieved on the UA/UP in 37 of 40 (92.5%) patients
using only the AH device. The entire TLH could be completed using
only AH device in 35 (87.5%) of patients. In 5 patients, an additional
energy device was needed to maintain hemostasis; bipolar was
used for 4 of those patients and monopolar for the 5th patient.
This study utilized the expertise of high volume surgeons to
assess the efﬁcacy of the AH device during a TLH. The majority of
cases were reported as medium or high complexity, with only
4 cases (10%) being low complexity. This is likely due to the
recruitment of high case-volume surgeons who routinely perform
more difﬁcult surgeries. Fifty three percent were for uterine
ﬁbroids implying that the majority of cases had enlarged uteri with
the largest uterine size being 564 g. Among the 21 subjects who
were identiﬁed as having a histological diagnosis of ﬁbroids, this
variability was also observed as the uterine weights ranged from
57 to 564 g, with a mean weight of 256.2 g and a median weight of
235.5 g. Uterine size did not appear to be associated with the need
for additional touchups. Table 2 indicates two subjects on the left
and two subjects on the right who required 3 additional touch ups.
The uterine weights for these 4 subjects were 68, 128, 183, and
490 g. These larger uteri physiologically have larger uterine
pedicles to maintain blood ﬂow to the uterus. The AH device
was effective despite reported uterine size and case difﬁculty.
The recommended vessel diameter for previous versions of the
harmonic shears was up to 5 mm. In one study, a failure rate of 22%was reported for sealing a 4–5 mm vessel with a harmonic scalpel
alone [11]. Often, surgeons will utilize ultrasonic energy for cutting
and dissection due to its proven beneﬁts, yet still will rely on a
second energy source for coagulation and vessel sealing of larger
vessels. Using two energy sources for one procedure is not only
cumbersome, but increases both the operating time and the cost of
the surgery. Data presented here suggest that the new advanced
hemostasis technology is able to reduce the need for alternate
energy sources during hysterectomy. In the majority of cases (65%)
the surgeons reported that the use of the AH device had led to
fewer instrument exchanges. It must be noted that the uterine
artery is one of the more difﬁcult vessels to effectively ligate or seal
in abdominal surgery. The uterine artery’s point of entry into the
end organ is located in dense ﬁbrous tissue making it more difﬁcult
to clearly isolate the main branch. It also lies in close proximity to
the ureter, leading to the common technique of increased traction
on the uterus to increase the distance between vessel and ureter to
avoid collateral damage. The result is that while using advanced
energy devices to seal and cut, the vessel may be transected before
a full seal has been achieved.
Surgeons’ preference during surgery may have inﬂuenced the
ﬁndings in the study. In particular, the utilization of the instrument
in different trocars may affect the hemostasis obtained. One
surgeon utilized the AH device in a center trocar; the others
utilized side trocars. Some surgeons kept the instrument in the
same trocar irrespective of the side of the pedicle being transected
while others changed trocar sites. Not optimizing the angle of
approach by changing trocar sites may theoretically affect the
number of touch ups needed for the ‘opposite’ pedicle as the view
is invariably obscured. Another potential cause of increased touch
ups is back bleeding from the initial pedicle transected. In this
study, however, there was no apparent association between the
side of ﬁrst transection and the lack of hemostasis on initial
application of the AH device or the failure to maintain hemostasis.
Interestingly, the majority of the touch ups were on the right side
(8 out of 9). Potentially the surgeons’ position at the operating
table, could explain a more difﬁcult angulation to approach the
vessel and a subsequent inferior seal/transection technique.
Of interest in this study is that, in half of the cases (by a single
surgeon [AK]), the colpotomy was systematically performed
vaginally as opposed to laparoscopically. The technique utilizes
a true intra-fascial approach around the cervix starting above the
insertion of the cardinal ligaments leaving the peri-cervical ring
and utero-sacral arch intact. This utilizes the excellent dissecting
and cutting capabilities of the harmonic technology. The same
approach is difﬁcult to achieve with advanced bipolar devices. The
remainder of the split thickness vagina is then easily incised
vaginally (by means of a cold knife) and sutured vaginally. This
approach may reduce the risk of vault dehiscence.
The safety proﬁle of the TLH is conﬁrmed in this study,
speciﬁcally when using harmonic technology. There were no intra
operative complications reported throughout the cases. No cases
were converted to open cases, no collateral damage secondary to
advanced energy use was reported, no blood transfusions were
needed and no re-operations were required. The post-operative
AEs were consistent with AEs reported in other studies describing
this technique [13,14]. However, the most concerning post-
operative AEs were one case of vaginal hemorrhage and one case
of infected hematoma formation.
The fact that it involved multiple surgeons adhering to their
own technique yields some external validity to the ﬁndings. The
ability to use these larger vessels as the endpoint in this study
successfully demonstrates the effectiveness of the instrument in a
range of clinical settings. Limitations of this study are its small
sample size and that there is no comparison group to further help
the clinician make a choice of which advanced energy product to
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criticized as the study was performed by high volume surgeons
who have experience utilizing laparoscopic energy during their
surgeries, so this study does not reﬂect a potential learning curve
inherent to all medical devices.
Procedure reviews by a third party to assess the primary and
secondary endpoints would have provided another level of
objectivity. Finally, it must be noted that the study was funded
by the manufacturer of the ultrasonic technology.
Taken together, the data presented in this study indicate that
the AH devices have clinical utility for TLH. Moreover, this work
adds to the body of evidence supporting the positive beneﬁt-risk
analysis of the minimally invasive approach to hysterectomy
[3]. The new algorithm to deliver energy in the AHM has shown the
potential to reduce the need for additional hemostatic devices or
products as well as the potential to reduce the need for multiple
instrument changes during surgery.
A brief video of one of the surgical procedures from this study is
included to show the AH Device being used during the Laparoscopic
Hysterectomy of a 49 year old woman with prolonged heavy periods
who opted for deﬁnitive management in the form of a laparoscopic
intrafascial hysterectomy and bilateral salpingo-oophorectomy.
The video demonstrates the AH Device is an appropriate instrument
for performing a Laparoscopic Hysterectomy intrafascial (LHi).
Utilising the LHi technique with the AH device results in
simultaneous vessel coagulation and cutting allowing for virtually
no instrument changes and seamless operating.
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